Inventor · disambiguated record
Aimesther Betancourt
Also filed as: BETANCOURT AIMESTHER · BETANCOURT AIMESTHER O · BETANCOURT AIMESTHER OJITO
17 granted patents·6 pending applications·53 citations·filing 2009–2023
92Inventor score
Files withKARUNA THERAPEUTICS INC6EIGER BIOPHARMACEUTICALS INC3BAUSCH HEALTH COMPANIES INC2ICO THERAPEUTICS INC2LAURENT PHARMACEUTICALS2
Top patents by PatentIndex Score
23 records- 0194US11517532B2Methods of treating hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Dec 6, 2022·3 cites·23 claims
- 0294US10925832B2Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·18 claims
- 0393US12029819B2Pharmaceutical compositions comprising lonafarnib and ritonavirEIGER BIOPHARMACEUTICALS INC·Filed 2022·Granted Jul 9, 2024·1 cites·20 claims
- 0493US11452692B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Sep 27, 2022·2 cites·18 claims
- 0592US11890378B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2022·Granted Feb 6, 2024·1 cites·14 claims
- 0691US11471413B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·2 cites·21 claims
- 0789US10933020B2Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2019·Granted Mar 2, 2021·5 cites·46 claims
- 0885US10835496B2Pharmaceutical compositions comprising lonafarnib and ritonavirEIGER BIOPHARMACEUTICALS INC·Filed 2016·Granted Nov 17, 2020·4 cites·24 claims
- 0983US10406127B2Solid oral formulation of fenretinideLAURENT PHARMACEUTICALS·Filed 2015·Granted Sep 10, 2019·3 cites·32 claims
- 1082US8460640B2Narcotic drug formulations with decreased abuse potentialVINSON ROBERT·Filed 2009·Granted Jun 11, 2013·14 cites·28 claims
- 1178US8703956B2Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acidBETANCOURT AIMESTHER·Filed 2012·Granted Apr 22, 2014·6 cites·26 claims
- 1277US10512619B2Solid oral formulation of fenretinideLAURENT PHARMACEUTICALS·Filed 2018·Granted Dec 24, 2019·3 cites·25 claims
- 1377US8980918B2Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acidATOPIX THERAPEUTICS LTD·Filed 2014·Granted Mar 17, 2015·3 cites·7 claims
- 1474US12151998B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoUNIV MICHIGAN REGENTS·Filed 2021·Granted Nov 26, 2024·0 cites·12 claims
- 1573US2021154146A1Compositions and methods for treating disorders ameliorated by muscarinic receptor activationKARUNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1666US2020255372A1Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoMILLENDO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1762US9546135B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoATTEROCOR INC·Filed 2015·Granted Jan 17, 2017·1 cites·8 claims
- 1857US2023241102A1Formulations of calcium and phosphate for oral inflammationBAUSCH HEALTH COMPANIES INC·Filed 2023·Application pending·0 cites
- 1954US10059660B2Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related theretoMILLENDO THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·0 cites·6 claims
- 2050US2023174493A1Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor InhibitorsINVERSAGO PHARMA INC·Filed 2021·Application pending·0 cites
- 2149US2021369615A1Solid oral formulations of amphotericin bICO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2244US11590165B2Formulations of calcium and phosphate for oral inflammationBAUSCH HEALTH COMPANIES INC·Filed 2015·Granted Feb 28, 2023·0 cites·10 claims
- 2344US2020155583A1Solid oral formulations of amphotericin bICO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →